273 related articles for article (PubMed ID: 17575166)
1. Regression of experimental medulloblastoma following transfer of HER2-specific T cells.
Ahmed N; Ratnayake M; Savoldo B; Perlaky L; Dotti G; Wels WS; Bhattacharjee MB; Gilbertson RJ; Shine HD; Weiss HL; Rooney CM; Heslop HE; Gottschalk S
Cancer Res; 2007 Jun; 67(12):5957-64. PubMed ID: 17575166
[TBL] [Abstract][Full Text] [Related]
2. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
3. [Chimeric T cell receptor N29gamma redirect T lymphocytes response specific to p185HER2 in A murine model of metastatic breast cancer].
Li SP; Urban FA; Macgregor JN; Hughes DP; McDonagh KT
Ai Zheng; 2004 Nov; 23(11 Suppl):1370-5. PubMed ID: 15566639
[TBL] [Abstract][Full Text] [Related]
4. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
Knutson KL; Disis ML
Clin Breast Cancer; 2001 Apr; 2(1):73-9. PubMed ID: 11899386
[TBL] [Abstract][Full Text] [Related]
5. Tumor ablation by gene-modified T cells in the absence of autoimmunity.
Wang LX; Westwood JA; Moeller M; Duong CP; Wei WZ; Malaterre J; Trapani JA; Neeson P; Smyth MJ; Kershaw MH; Darcy PK
Cancer Res; 2010 Dec; 70(23):9591-8. PubMed ID: 21098715
[TBL] [Abstract][Full Text] [Related]
6. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.
Ahmed N; Salsman VS; Kew Y; Shaffer D; Powell S; Zhang YJ; Grossman RG; Heslop HE; Gottschalk S
Clin Cancer Res; 2010 Jan; 16(2):474-85. PubMed ID: 20068073
[TBL] [Abstract][Full Text] [Related]
7. Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells.
Ishida A; Tanaka H; Hiura T; Miura S; Watanabe S; Matsuyama K; Kuriyama H; Tanaka J; Kagamu H; Gejyo F; Yoshizawa H
Scand J Immunol; 2007 Nov; 66(5):546-54. PubMed ID: 17953530
[TBL] [Abstract][Full Text] [Related]
8. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
9. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
[TBL] [Abstract][Full Text] [Related]
10. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy.
Spaapen R; van den Oudenalder K; Ivanov R; Bloem A; Lokhorst H; Mutis T
Clin Cancer Res; 2007 Jul; 13(13):4009-15. PubMed ID: 17606735
[TBL] [Abstract][Full Text] [Related]
11. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
Stastny MJ; Brown CE; Ruel C; Jensen MC
J Pediatr Hematol Oncol; 2007 Oct; 29(10):669-77. PubMed ID: 17921847
[TBL] [Abstract][Full Text] [Related]
12. Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells.
Wang LX; Shu S; Plautz GE
Cancer Res; 2005 Oct; 65(20):9547-54. PubMed ID: 16230420
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.
Yoon SH; Lee JM; Cho HI; Kim EK; Kim HS; Park MY; Kim TG
Cancer Gene Ther; 2009 Jun; 16(6):489-97. PubMed ID: 19096447
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma.
Rainusso N; Brawley VS; Ghazi A; Hicks MJ; Gottschalk S; Rosen JM; Ahmed N
Cancer Gene Ther; 2012 Mar; 19(3):212-7. PubMed ID: 22173710
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of dual-specific T cells and influenza virus.
Murphy A; Westwood JA; Brown LE; Teng MW; Moeller M; Xu Y; Smyth MJ; Hwu P; Darcy PK; Kershaw MH
Cancer Gene Ther; 2007 May; 14(5):499-508. PubMed ID: 17332777
[TBL] [Abstract][Full Text] [Related]
16. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
17. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation.
Feuchtinger T; Richard C; Joachim S; Scheible MH; Schumm M; Hamprecht K; Martin D; Jahn G; Handgretinger R; Lang P
J Immunother; 2008; 31(2):199-206. PubMed ID: 18481389
[TBL] [Abstract][Full Text] [Related]
18. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer.
Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L
Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314
[TBL] [Abstract][Full Text] [Related]
19. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
20. Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.
Pinthus JH; Waks T; Kaufman-Francis K; Schindler DG; Harmelin A; Kanety H; Ramon J; Eshhar Z
Cancer Res; 2003 May; 63(10):2470-6. PubMed ID: 12750268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
